Treatment of eosinophil or mast cell related disorders
Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
1. A method of protecting against, treating, or managing an eosinophil related disorder caused by eosinophils in the gastrointestinal tract in response to an allergen, comprising administering to a human subject having the disorder a therapeutically effective amount of a monoclonal antibody which specifically binds to a human KIT receptor comprising SEQ ID NO: 1, or an antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof each comprises a light chain variable region (“VL”) comprising VL CDRs 1-3 comprising SEQ ID NOs: 2-4, respectively, and a heavy chain variable region (“VH”) comprising VH CDRs 1-3 comprising SEQ ID NOs: 5-7, respectively.
2. The method of claim 1 , wherein the method is for treating an eosinophil related disorder in a human subject in need of treatment of the eosinophil related disorder.
3. The method of claim 1 , wherein the antibody is a humanized antibody.
4. The method of claim 1 , wherein the antibody comprises a VL comprising a VL sequence selected from the group consisting of SEQ ID NOs: 13, 14, 15, and 16; and a VH comprising a VH sequence selected from the group consisting of SEQ ID NOs: 8, 9, 10, 11, and 12.
5. The method of claim 1 , wherein the subject is a human adult.
6. The method of claim 1 , wherein the human subject is a child.
7. The method of claim 1 , comprising administering a therapeutically effective amount of the antibody which specifically binds to a human KIT receptor comprising SEQ ID NO:1.